Ariana Boswell

All articles by Ariana Boswell

• More research needed on long-term effects of TTR depletion in ATTR-CM treatment

  A review highlights the many roles of transthyretin in the body and the potential implications of long-term suppression in patients with ATTR.

• Heart valve repair technique found safe and effective in patients with ATTR-CM

  A minimally invasive technique for treating mitral valve regurgitation was found to work successfully in patients with ATTR-CM.

• Webinar explores clinical trial landscape for ATTR-CM

  In a recent webinar, Kristen Hsu of the Amyloidosis Research Consortium discussed the clinical trials currently being conducted for ATTR-CM.

• How to handle anxiety during the wait for ATTR-CM test results

  It’s normal to feel anxious while waiting for scan results.

• Webinar outlines current and emerging treatments for ATTR-CM

  In a recent webinar hosted by the Amyloidosis Research Consortium, Jan Griffin, MD discussed the expanding therapeutic landscape for ATTR-CM.

• Florbetaben (18F) receives orphan drug designation to diagnose ATTR

  The European Union has granted Orphan Drug Designation to the radioactive tracer florbetaben (18F) for the diagnosis of ATTR-CM.

• Review calls for more research on SGLT2 inhibitor use in ATTR-CM

  While SGLT2i may improve survival and cardiovascular outcomes in ATTR-CM, further research is needed to fully evaluate its clinical utility.

• Study finds new SPECT/CT approach may improve ATTR-CM diagnosis

  A recent study developed a simple mathematical tool that accurately detects cases of ATTR-CM based on SPECT/CT imaging.

• UK approves acoramidis to treat ATTR-CM

  Acoramidis, a transthyretin stabilizer, has been approved for adults living with ATTR-CM in the United Kingdom.

• Age, left atrium size associated with atrial fibrillation in ATTR-CM

  In a recent study, left atrial dilation and advanced age were identified as predictors of atrial fibrillation in patients with ATTR-CM.